Health experts expect COVID cases to rise this summer, but say the surge won’t be as devastating as previous ones. Unlike previous summers, the majority of the U.S. population has some immunity against COVID-19 from vaccines, boosters and previous infections. (USA Today)
The next phase of a federal opioid trial will determine how much Walmart, CVS and Walgreens pay to two Ohio counties. A federal judge will begin hearing arguments Tuesday to determine how much money it will take to reverse the effects of the opioid crisis that devastated Lake and Trumbull counties. (Cleveland.com)
The World Health Organization and Gavi are not planning to buy COVID vaccine from South Africa’s Aspen Pharmacare. Aspen said last week that it would be forced to repurpose about half of its vaccine production capacity if orders did not pick up. (Reuters)
BioNTech stock rose as Q1 revenues soared, but the company expects vaccine demand to decline later this year. BioNTech added that it is on track to deliver more than 2 billion doses of COVID vaccine to low- and middle-income countries by the end of 2022. (Seeking Alpha)
Civica Rx believes it can solve the U.S. insulin crisis. The nonprofit drug manufacturer is planning to produce generic insulin for no more than $30 for a month’s supply. (The Daily Beast)
